{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:27:16Z","timestamp":1791358036731,"version":"4.3.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jneuroim.2025.578679","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:28:36Z","timestamp":1751372916000},"page":"578679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Paraneoplastic bilateral vocal cord paralysis in a patient with anti-Hu syndrome after receiving nivolumab: Case report and literature review"],"prefix":"10.1016","volume":"406","author":[{"given":"Seyda","family":"Erdo\u011fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Peker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Demirkaz\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nursel","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canan","family":"Y\u00fccesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jneuroim.2025.578679_bb0005","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.21037\/tlcr-21-222","article-title":"Acute anti-Ma2 paraneoplastic encephalitis associated to pembrolizumab: a case report and review of the literature","volume":"10","author":"Albarr\u00e1n","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"13","key":"10.1016\/j.jneuroim.2025.578679_bb0010","article-title":"Neurologic toxicity of immune checkpoint inhibitors: a review of literature","volume":"14","author":"Albarr\u00e1n","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578679_bb0015","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0194-5998(03)01319-6","article-title":"Bilateral vocal cord paresis as a presenting sign of paraneoplastic syndrome: case report","volume":"130","author":"Chang","year":"2004","journal-title":"Otolaryngol. Head Neck Surg."},{"issue":"12","key":"10.1016\/j.jneuroim.2025.578679_bb0020","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.jtho.2018.08.2032","article-title":"Bilateral vocal cord paralysis: pembrolizumab-induced delayed-onset toxicity in a patient with lung adenocarcinoma","volume":"13","author":"Hamada","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"4 Pt 1","key":"10.1016\/j.jneuroim.2025.578679_bb0025","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/000348947608500402","article-title":"Etiology of bilateral abductor vocal cord paralysis: a review of 389 cases","volume":"85","author":"Holinger","year":"1976","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578679_bb0030","article-title":"Paraneoplastic syndrome presenting as bilateral vocal cord paralysis","volume":"78","author":"Kaur","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2025.578679_bb0035","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1007\/s12070-024-04709-5","article-title":"Velopalatine and bilateral vocal cord paralysis associated with atezolizumab treatment: a severe and previously undocumented side effect in cancer immunotherapy","volume":"76","author":"Lorente-Piera","year":"2024","journal-title":"Indian J. Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.jneuroim.2025.578679_bb0040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s40425-019-0821-8","article-title":"Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study","volume":"3","author":"Manson","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jneuroim.2025.578679_bb0045","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s13760-024-02590-1","article-title":"A rare case of immune checkpoint inhibitor-induced meningoradiculitis with vocal cord diplegia","volume":"124","author":"Pichon","year":"2024","journal-title":"Acta Neurol. Belg."},{"issue":"358","key":"10.1016\/j.jneuroim.2025.578679_bb0050","article-title":"A paraneoplastic syndrome misdiagnosed as ALS: what are the red flags? A case report and review of the literature","volume":"15","author":"Tolkovsky","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"12","key":"10.1016\/j.jneuroim.2025.578679_bb0055","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/archotol.131.12.1086","article-title":"Idiopathic vocal cord palsies and associated neurological conditions","volume":"131","author":"Urquhart","year":"2005","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578679_bb0060","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000604","article-title":"Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors","volume":"7","author":"Vogrig","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2025.578679_bb0065","article-title":"Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors","volume":"24","author":"Vogrig","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578679_bb0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/CJI.0000000000000310","article-title":"Bilateral vocal cord paralysis due to an immune-related adverse event of nivolumab: a case report","volume":"43","author":"Willegers","year":"2020","journal-title":"J. Immunother."},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578679_bb0075","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CJI.0000000000000323","article-title":"Bilateral vocal cord paralysis due to an immune-related adverse event of nivolumab: a case report","volume":"43","author":"Willegers","year":"2020","journal-title":"J. Immunother."},{"key":"10.1016\/j.jneuroim.2025.578679_bb0080","article-title":"Bilateral vocal cord paralysis and cervicolumbar radiculopathy as the presenting paraneoplastic manifestations of small cell lung cancer: a case report and literature review","volume":"2016","author":"Yeung","year":"2016","journal-title":"Case Rep. Otolaryngol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825001602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825001602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T21:54:49Z","timestamp":1753134889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572825001602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":16,"alternative-id":["S0165572825001602"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578679","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paraneoplastic bilateral vocal cord paralysis in a patient with anti-Hu syndrome after receiving nivolumab: Case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"578679"}}